Scalp, Eyebrow, and Eyelash Hair Regrowth with Continued Ritlecitinib Treatment Among Patients with Alopecia Areata Without Target Efficacy Response at Week 24: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
September 2023
in “
Journal of the American Academy of Dermatology
”
Studysummary In this study, patients with alopecia areata who didn't initially respond to ritlecitinib at Week 24 showed improved response rates by Week 48, with up to 34% achieving better hair regrowth outcomes.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on jaad.org →